CY1112605T1 - Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων - Google Patents

Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων

Info

Publication number
CY1112605T1
CY1112605T1 CY20111100984T CY111100984T CY1112605T1 CY 1112605 T1 CY1112605 T1 CY 1112605T1 CY 20111100984 T CY20111100984 T CY 20111100984T CY 111100984 T CY111100984 T CY 111100984T CY 1112605 T1 CY1112605 T1 CY 1112605T1
Authority
CY
Cyprus
Prior art keywords
active
ketotifaine
iseter
visually
hydroxy
Prior art date
Application number
CY20111100984T
Other languages
English (en)
Inventor
A K Gunnar Aberg
George E Wright
Jan L Chen
Andrew T Maioli
Original Assignee
Bridge Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma, Inc. filed Critical Bridge Pharma, Inc.
Publication of CY1112605T1 publication Critical patent/CY1112605T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ρακεμική νορκετοτιφαίνη, ρακεμική 10-υδροξυ-κετοτιφαίνη, ρακεμική 10-υδροξυ-νορ-κετοτιφαίνη και οπτικώς ενεργά ισομερή κετοτιφαίνης, νορκετοτιφαίνης, 10-υδροξυ-κετοτιφαίνης και 10-υδροξυ-νορκετοτιφαίνης βρέθηκαν να έχουν αντιαλλεργικές και αντι-φλεγμονώδεις επιδράσεις όντας συγχρόνως απαλλαγμένες από τις σοβαρές δοσο-περιοριστικές κατασταλτικές παρενέργειες της κετοτιφαίνης.
CY20111100984T 1999-09-13 2011-10-17 Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων CY1112605T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15356699P 1999-09-13 1999-09-13
US19736300P 2000-04-15 2000-04-15
US19798500P 2000-04-15 2000-04-15
US19790600P 2000-04-15 2000-04-15
US19790500P 2000-04-15 2000-04-15
EP00966709A EP1218007B1 (en) 1999-09-13 2000-09-12 Optically active isomers of ketotifen and therapeutically active metabolites thereof

Publications (1)

Publication Number Publication Date
CY1112605T1 true CY1112605T1 (el) 2016-02-10

Family

ID=27538454

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100984T CY1112605T1 (el) 1999-09-13 2011-10-17 Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων

Country Status (18)

Country Link
US (3) US7226934B1 (el)
EP (1) EP1218007B1 (el)
JP (1) JP5116928B2 (el)
CN (1) CN1391475A (el)
AR (1) AR034396A1 (el)
AT (1) ATE516804T1 (el)
AU (1) AU782816B2 (el)
BR (1) BR0013935A (el)
CA (1) CA2383222C (el)
CY (1) CY1112605T1 (el)
DK (1) DK1218007T3 (el)
HU (1) HUP0202671A3 (el)
IL (2) IL148368A0 (el)
MX (1) MXPA02002658A (el)
MY (1) MY134888A (el)
PL (1) PL353586A1 (el)
PT (1) PT1218007E (el)
WO (1) WO2001019367A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516804T1 (de) * 1999-09-13 2011-08-15 Bridge Pharma Inc Optisch aktive isomere von ketotifen und deren therapeutisch wirksame metabolite
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
EP2294419B1 (en) * 2008-06-13 2013-08-14 Case Western Reserve University Compostions and methods for treating corneal inflammation
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
EP2408302A4 (en) * 2009-03-17 2012-08-15 Aciex Therapeutics Inc OPHTALMIC FORMULATIONS OF KTOTICENE AND METHODS OF USE
CN103619839B (zh) * 2011-06-28 2016-06-01 福建省闽东力捷迅药业有限公司 抗-变态反应的苯并环庚并噻吩衍生物
US8557846B1 (en) * 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US20140120121A1 (en) * 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
CN104059056B (zh) * 2014-06-26 2017-08-25 福建省闽东力捷迅药业有限公司 一种富马酸卢帕替芬晶型b及其制备方法
AU2016276022C1 (en) * 2015-06-11 2021-04-22 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus in mammals
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
CA3036230A1 (en) 2016-09-08 2018-03-15 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of hypercytokinemia and viral infection
WO2018075574A1 (en) 2016-10-18 2018-04-26 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1089483A (en) 1964-02-04 1967-11-01 Sandoz Ltd Improvements in or relating to 4h-benzo(4,5)cyclohepta (1,2-b) thiophene derivatives
FR1447527A (fr) 1964-08-11 1966-07-29 Sandoz Sa Nouveaux benzo-cyclohepta-thiophènes et leur préparation
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
BE794377A (fr) 1972-01-24 1973-07-23 Sandoz Sa Nouveaux derives du benzo-cyclohepta-thiophene
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4073915A (en) 1975-05-20 1978-02-14 Sandoz Ltd. Treating asthma
US4128549A (en) 1976-02-27 1978-12-05 Sandoz Ltd. Precursors of 4-(1-alkyl-4-piperidylidene-4H-benzo[4,5]cyclohepta-[1,2-b]thiophen-10(9H)-ones
CS263993B1 (cs) * 1988-03-11 1989-05-12 Polivka Zdenek Způsob přípravy čistých enantiomerů 4- (l-meíhyl-4-piperidyliden) -4,9-dihydrobenzo [ 4,5) cyklohepta [ 1,2-b ] - thiofen-lQ-onu
SG44477A1 (en) * 1988-04-28 1997-12-19 Schering Corp Fused polycyclic compounds compositions methods of manufacture and their use as paf antaginists anthihistamines and/or antiinflammatory agents
GB9012926D0 (en) * 1990-06-09 1990-08-01 Scras Pyrrolo-pyridine derivatives
CA2093646A1 (en) * 1990-10-10 1992-04-11 Jesse K. Wong Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
DK0616524T3 (da) * 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
BR9807911A (pt) * 1997-04-03 2000-02-22 Bridge Pharma Inc Compostos benzocicloheptatiofeno
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
ATE516804T1 (de) * 1999-09-13 2011-08-15 Bridge Pharma Inc Optisch aktive isomere von ketotifen und deren therapeutisch wirksame metabolite

Also Published As

Publication number Publication date
US7226934B1 (en) 2007-06-05
PT1218007E (pt) 2011-10-27
HUP0202671A2 (hu) 2002-11-28
MY134888A (en) 2007-12-31
CA2383222C (en) 2008-11-18
EP1218007B1 (en) 2011-07-20
CN1391475A (zh) 2003-01-15
EP1218007A1 (en) 2002-07-03
AU7701400A (en) 2001-04-17
ATE516804T1 (de) 2011-08-15
US7557128B2 (en) 2009-07-07
BR0013935A (pt) 2002-05-14
US20080287498A1 (en) 2008-11-20
DK1218007T3 (da) 2011-11-07
AR034396A1 (es) 2004-02-25
IL148368A0 (en) 2002-09-12
PL353586A1 (en) 2003-12-01
AU782816B2 (en) 2005-09-01
WO2001019367A1 (en) 2001-03-22
JP5116928B2 (ja) 2013-01-09
MXPA02002658A (es) 2002-10-23
IL148368A (en) 2007-10-31
US20090149502A1 (en) 2009-06-11
CA2383222A1 (en) 2001-03-22
EP1218007A4 (en) 2003-04-09
JP2003509369A (ja) 2003-03-11
US7872025B2 (en) 2011-01-18
HUP0202671A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
CY1112605T1 (el) Οπτικως ενεργα ισομερη κετοτιφαινης και θεραπευτικως δραστικοι μεταβολιτες αυτων
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
RS53895B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
ATE234092T1 (de) 2-alkylpyrrolidine
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
RS49795B (sr) Sredstva sa antidepresivnim dejstvom
TR199900400T2 (xx) Heterosiklik metaloproteaz inhibit�rleri.
TR199900383T2 (xx) 1,3-Diheterosiklik metaloproteaz inhibit�rleri.
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
UY26380A1 (es) Inhibidores de fab i
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
ID25853A (id) Penghambat saluran kalium
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
NO976074L (no) To- og treverdige småmolekylinhibitorer for selektin
DE69808065D1 (de) Trisubstituierte phenyl derivate mit retinoid agonist, antagonist oder inversagonist biologischer aktivität
TR199900429T2 (xx) Spirosiklik metaloproteaz inhibit�rleri.
NO20042497L (no) 4,4-diflour-1,2,3,4-tetrahydro-5H-1-benzazepinderivater og salter av disse
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
CY1116418T1 (el) Διεργασια για την παραγωγη r-(+)-6-καρβοξαμιδο-3-ν-μεθυλαμινο-1,2,3,4-τετραϋδροκαρβαζολιου
EA200100854A1 (ru) Кальций-литические соединения
DE602004013431D1 (de) Identifikation von therapeutische verbindungen.
EA200200798A1 (ru) Кальцилитические соединения